Human papillomavirus testing for primary cervical cancer screening

Current Oncology Reports

Volumn 10, Issue 6, 2008, Pages 533-537

  Runowicz, Carolyn D ^a   Garozzo, Stephanie ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

CANCER INCIDENCE; CANCER SCREENING; CLINICAL TRIAL; COLPOSCOPY; CONDYLOMA ACUMINATUM; DRUG EFFICACY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VACCINATION; VIRUS DETECTION; WART VIRUS;

CERVIX UTERI; DNA, VIRAL; FEMALE; HUMANS; MASS SCREENING; MEDICAL ONCOLOGY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 58649111688     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-008-0081-0     Document Type: Review

References (26)

1. Nanda K, McCrory DC, Myers ER, et al.: Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: A systematic review. Ann Int Med 2000, 132: 810-819.
2. National Institutes of Health Consensus Statement: Cervical Cancer. April 1-3, 1996, 14: 1-38.
3. Walboomers JM, Jacobs MV, Manos MM, et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189: 12-19.
4. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al.: Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: A prospective study. Lancet 1999, 354: 20-25.
5. Koliopoulos G, Arbyn M, Martin-Hirsch P, et al.: Diagnostic accuracy of human papillomavirus testing in primary cervical screening: A systematic review and meta-analysis of non-randomized studies. Gynecol Oncol 2007, 104: 232-246.
6. Mayrand MH, Duarto-Franco E, Rodrigues I, et al.: Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007, 357: 1579-1588.
7. Mayrand MH, Duarte-Franco E, Coutlee F, et al.: Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: Design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int J Cancer 2006, 119: 615-623.
8. Naucler P, Ryd W, Törnberg S, et al.: Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007, 357: 1589-1607.
9. Ronco G, Giorgi-Rossi F, Carozzi F, et al.: Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Instit 2008, 100: 492-501.
10. Kitchener HC, Almonte M, Wheeler P, et al.: HPV testing in routine cervical screening: Cross sectional data from the ARTISTIC trial. Br J Cancer 2006, 95: 56-61.
11. Kitchener HC, Almonte M, Desai M, et al.: The final results of the ARTISTIC Trial: A randomized trial of HPV testing and primary cervical screening. Acta Cytologic 2007, 51(Suppl 2): 281.
12. Kotaniemi-Talonen L, Anttila A, Nalial N, et al.: Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3. Eur J Cancer 2008, 44: 565-571.
13. Bulkmans NW, Berkhof J, Rozendaal L, et al.: Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomized controlled implementation trial. Lancet 2007, 370: 1764-1772.
14. Harper DM, Franco EL, Wheeler CM, et al.: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomized controlled trial. Lancet 2004, 364: 1757-1765.
15. Villa LL, Costa RL, Petta CA, et al.: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005, 6: 271-278.
16. The Future II Study Group: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356: 1915-1927.
17. Garland SM, Hernandez-Avila M, Wheeler CM, et al.: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356: 1928-1943.
18. Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007, 56: 1-24.
19. Saslow D, Castle PE, Cox T, et al.: American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007, 57: 7-28.
20. Harper DM, Franco EL, Wheeler CM, et al.: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomized control trial. Lancet 2006, 367: 1247-1255.
21. Villa LL, Costa RL, Petta CA, et al.: High sustained effi-cacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006, 95: 1459-1466.
22. Ries L, Harkins D, Krapcho M, et al.: SEER cancer statistics review, 1975-2003. National Cancer Institute, 2006.
23. Paavonen J, Jenkins D, Bosch FX, et al.: Efficacy of a prophylactic adjuvant bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomized controlled trial. Lancet 2007, 369: 2161-2170.
24. Kulasingham SL, Myers ER: Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003, 290: 781-789.
25. Saslow D, Runowicz CD, Solomon D, et al.: American Cancer Society Guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002, 52: 342-362.
26. Smith RA, Cokkinides V, Brawley OW: Cancer screening in the United States, 2008: A review of current American Cancer Society Guidelines and cancer screening issues. CA Cancer J Clin 2008, 58: 161-179.